{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:06:48Z","timestamp":1771456008205,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.clml.2015.10.001","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T17:00:57Z","timestamp":1445878857000},"page":"70-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Atrial Fibrillation in Hematologic Malignancies, Especially After Autologous Hematopoietic Stem Cell Transplantation: Review of Risk Factors, Current Management, and Future Directions"],"prefix":"10.1016","volume":"16","author":[{"given":"Pankaj","family":"Mathur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Paydak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.10.001_bib1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: AF in cancer","volume":"63","author":"Farmakis","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clml.2015.10.001_bib2","doi-asserted-by":"crossref","first-page":"e102861","DOI":"10.1371\/journal.pone.0102861","article-title":"AF as a marker of occult cancer","volume":"9","author":"Ostenfeld","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2015.10.001_bib3","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/bmt.2015.127","article-title":"Arrhythmias in the setting of hematopoietic cell transplants","volume":"50","author":"Tonorezos","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2015.10.001_bib4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00277-004-0867-6","article-title":"AF following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease)","volume":"84","author":"Montella","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2015.10.001_bib5","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/sj.bmt.1701217","article-title":"Paroxysmal AF after high-dose melphalan in five patients autotransplanted with blood progenitor cells","volume":"21","author":"Olivieri","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2015.10.001_bib6","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1080\/10428190500235884","article-title":"Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older","volume":"46","author":"Mileshkin","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.10.001_bib7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/sj.bmt.1704623","article-title":"Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes","volume":"34","author":"Hidalgo","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2015.10.001_bib8","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.bbmt.2013.05.019","article-title":"Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation","volume":"19","author":"Singla","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2015.10.001_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1753944712464102","article-title":"AF following autologous stem cell transplantation in patients with multiple myeloma: incidence and risk factors","volume":"6","author":"Sureddi","year":"2012","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.clml.2015.10.001_bib10","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/bmt.2012.253","article-title":"Factors affecting the development of\u00a0AF and atrial flutter (AF\/AFL) following autologous hematopoietic SCT (auto-HSCT)","volume":"48","author":"Steuter","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2015.10.001_bib11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.21459","article-title":"Acute weight gain and diastolic dysfunction as a potent risk complex for post stem cell transplant atrial fibrillation","volume":"84","author":"Fatema","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2015.10.001_bib12","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2009.05.040","article-title":"Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring","volume":"104","author":"Goldsmith","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clml.2015.10.001_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-155-1-201107050-00004","article-title":"Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation","volume":"155","author":"Chow","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2015.10.001_bib14","first-page":"902","article-title":"Acute cardiotoxicity of anthracyclines\u2014analysis by using Holter ECG","volume":"11","author":"Okuma","year":"1984","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.clml.2015.10.001_bib15","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.10.001_bib16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/CIRCHEARTFAILURE.112.966622","article-title":"Phosphoinositide 3-kinase p110\u03b1 is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction","volume":"5","author":"Weeks","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.clml.2015.10.001_bib17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/bmt.2009.97","article-title":"Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation","volume":"45","author":"Peres","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2015.10.001_bib18","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.2010.491","article-title":"Worldwide Network of Blood and Marrow Transplantation. Hematopoietic stem cell transplantation: a global perspective","volume":"303","author":"Gratwohl","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2015.10.001_bib19","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S0735-1097(03)00955-0","article-title":"Competing autonomic mechanisms precede the onset of postoperative atrial fibrillation","volume":"42","author":"Amar","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clml.2015.10.001_bib20","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","article-title":"AF Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation","volume":"347","author":"Wyse","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.10.001_bib21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1540-8159.2012.03513.x","article-title":"Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis","volume":"36","author":"Chatterjee","year":"2013","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.clml.2015.10.001_bib22","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/heartjnl-2013-305152","article-title":"What can rhythm control therapy contribute to prognosis in atrial fibrillation?","volume":"101","author":"Rolf","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.clml.2015.10.001_bib23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/MAJ.0b013e31828a7656","article-title":"Efficacy and safety of ibutilide for chemical cardioversion of AF and atrial flutter in cancer patients","volume":"347","author":"Bickford","year":"2014","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.clml.2015.10.001_bib24","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clml.2015.10.001_bib25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clml.2015.10.001_bib26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archinte.158.6.585","article-title":"Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study","volume":"158","author":"Silverstein","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clml.2015.10.001_bib27","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1055\/s-0037-1613830","article-title":"Derivation of a simple clinical model to categorize patients' probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer","volume":"83","author":"Wells","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clml.2015.10.001_bib28","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1055\/s-0037-1614065","article-title":"Predicting adverse outcome in patients with acute pulmonary embolism: a risk score","volume":"84","author":"Wicki","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clml.2015.10.001_bib29","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1160\/TH08-05-0285","article-title":"Prospective validation of the pulmonary embolism severity index: a clinical prognostic model for pulmonary embolism","volume":"100","author":"Donze","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clml.2015.10.001_bib30","first-page":"94","article-title":"Bleeding complications in patients with hematologic malignancies","volume":"39","author":"Franchini","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clml.2015.10.001_bib31","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.10.001_bib32","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J\u00a0Med"},{"key":"10.1016\/j.clml.2015.10.001_bib33","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacc.2013.11.013","article-title":"Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)","volume":"63","author":"Goodman","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clml.2015.10.001_bib34","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","article-title":"Incidence of\u00a0recurrent thromboembolic and bleeding complications among patients with\u00a0venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis","volume":"18","author":"Hutten","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clml.2015.10.001_bib35","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.1412S3","article-title":"Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.clml.2015.10.001_bib36","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Lyman","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.10.001_bib37","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2013.08.1623","article-title":"The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores\u00a0in anticoagulated patients with atrial fibrillation","volume":"62","author":"Rold\u00e1n","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clml.2015.10.001_bib38","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/CIRCULATIONAHA.109.873265","article-title":"N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health study","volume":"120","author":"Patton","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.clml.2015.10.001_bib39","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1007\/s00268-015-2943-6","article-title":"B-type natriuretic peptide-guided risk assessment for postoperative complications in lung cancer surgery","volume":"39","author":"Nojiri","year":"2015","journal-title":"World J Surg"},{"key":"10.1016\/j.clml.2015.10.001_bib40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/13547500903509351","article-title":"Atrial fibrillation after thoracic surgery for lung cancer: use of a single cut-off value of N-terminal pro-B type natriuretic peptide to identify patients at risk","volume":"15","author":"Salvatici","year":"2010","journal-title":"Biomarkers"},{"key":"10.1016\/j.clml.2015.10.001_bib41","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1161\/CIRCULATIONAHA.111.038729","article-title":"Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy","volume":"125","author":"Hijazi","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clml.2015.10.001_bib42","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/ajh.20635","article-title":"AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes","volume":"81","author":"Sanchorawala","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2015.10.001_bib43","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.amjcard.2004.10.028","article-title":"Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement","volume":"95","author":"Murtagh","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clml.2015.10.001_bib44","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.ehj.2004.04.007","article-title":"Amyloid deposition as a cause of atrial remodeling in persistent valvular atrial fibrillation","volume":"25","author":"Leone","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clml.2015.10.001_bib45","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","article-title":"Cardiac amyloidosis: updates in diagnosis and management","volume":"106","author":"Mohty","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.clml.2015.10.001_bib46","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy","volume":"63","author":"Rubinow","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.clml.2015.10.001_bib47","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/0002-9149(85)90995-6","article-title":"Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents","volume":"55","author":"Gertz","year":"1985","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clml.2015.10.001_bib48","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.amjmed.2011.04.013","article-title":"Cardiac amyloidosis: a practical approach to diagnosis and management","volume":"124","author":"Kapoor","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2015.10.001_bib49","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/leu.2011.219","article-title":"How to manage primary amyloidosis","volume":"26","author":"Gertz","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.10.001_bib50","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/sj.bmt.1702005","article-title":"High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant","volume":"24","author":"Saba","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2015.10.001_bib51","first-page":"1924","article-title":"Stem-cell transplantation for amyloidosis: improving outcomes but not for the faint of heart","volume":"29","author":"Bar","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.10.001_bib52","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.10.001_bib53","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.10.001_bib54","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.10.001_bib55","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research study","volume":"33","author":"D'Souza","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.10.001_bib56","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8 year study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2015.10.001_bib57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10741-014-9464-5","article-title":"Natural history and therapy of AL cardiac amyloidosis","volume":"20","author":"Grogan","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.clml.2015.10.001_bib58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death","volume":"5","author":"Kristen","year":"2008","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.clml.2015.10.001_bib59","article-title":"Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy","author":"Barbhayia","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.clml.2015.10.001_bib60","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1093\/europace\/euu175","article-title":"B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies","volume":"16","author":"Sinner","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.clml.2015.10.001_bib61","doi-asserted-by":"crossref","first-page":"235018","DOI":"10.1155\/2013\/235018","article-title":"The role of BNP and CRP in predicting the development of atrial fibrillation in patients undergoing isolated coronary artery bypass surgery","volume":"2013","author":"Pilatis","year":"2013","journal-title":"ISRN Cardiol"},{"key":"10.1016\/j.clml.2015.10.001_bib62","first-page":"CD003611","article-title":"Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery","volume":"1","author":"Arsenault","year":"2013","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015013191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015013191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T20:12:12Z","timestamp":1567282332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015013191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S2152265015013191"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.10.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atrial Fibrillation in Hematologic Malignancies, Especially After Autologous Hematopoietic Stem Cell Transplantation: Review of Risk Factors, Current Management, and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}